{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-082956","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.917598+00:00","generated_at":"2026-05-17T08:47:39.017378+00:00","sec_items":["1.01","2.01","3.02","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CorMedix completes $300M acquisition of Melinta; raises FY2025 revenue guidance","bullets":["Acquisition closed Aug 29, 2025; $260M cash + $40M equity upfront, plus up to $25M in milestone payments.","Pro forma 2025 revenue guidance raised to $325-350M; synergies expected $35-45M annually.","Transaction expected near-term accretive to EPS with double-digit accretion in 2026.","Susan Blum appointed CFO, Elizabeth Hurlburt COO, Matthew David CBO effective immediately.","Contingent payments include tiered royalties on REZZAYO US net sales and low-single-digit royalties on MINOCIN US net sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-082956","json":"https://secwatch.observer/filing/0001213900-25-082956.json","markdown":"https://secwatch.observer/filing/0001213900-25-082956.md","text":"https://secwatch.observer/filing/0001213900-25-082956.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390025082956/0001213900-25-082956-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390025082956/ea0255371-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:47:39.017378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2bcb77f8c5ed5b40378b753865cbc05f5783b7be","claim":"CorMedix Inc. underwent a change of control involving Melinta Therapeutics, LLC for $260 million in cash and $40 million worth of common shares (closed 2025-08-29).","evidence_excerpt":"at the effective time of the Merger (the “Effective Time”), the Company (i) paid to the Melinta equityholders (including the Consenting Melinta Members) an aggregate of $260 million in cash (subject to adjustment for the Aggregate Exercise Price, Estimated Company Cash, Estimated Company Debt, Estimated Working Capital as compared to the Working Capital","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1410098/000121390025082956/0001213900-25-082956-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Melinta Therapeutics, LLC"},{"label":"Consideration","value":"$260 million in cash and $40 million worth of common shares"},{"label":"Closing","value":"2025-08-29"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}